UTMDHIGH SIGNALFINANCIAL10-K

UTMD's revenue surged 293% to $38.5M while the aggregate market value of non-affiliate shares dropped 22% to $168M, creating a significant disconnect between operational performance and market valuation.

This dramatic revenue growth coupled with declining market valuation suggests either extraordinary business expansion or potential accounting/reporting changes that warrant immediate investigation. The substantial outperformance versus market perception indicates either a major undervaluation opportunity or underlying issues not apparent in the headline numbers.

Comparing 2026-03-27 vs 2025-03-26View on EDGAR →
FINANCIAL ANALYSIS

Revenue and gross profit both exploded 293% to $38.5M and $22M respectively, yet operating income declined 16% to $11.4M, suggesting significant increases in operating expenses that absorbed much of the revenue gains. The company maintained strong financial discipline with a 36% reduction in total liabilities to $3.3M and reduced share buybacks by 58% to $8.4M, while interest expense dropped 78% indicating improved capital efficiency. Overall, this presents a mixed picture of explosive top-line growth tempered by margin compression and reduced capital returns to shareholders.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+292.6%
$9.8M$38.5M

Strong top-line growth of 292.6% — accelerating demand or successful expansion into new markets.

Gross Profit
P&L
+292.6%
$5.6M$22.0M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Interest Expense
P&L
-77.5%
$289K$65K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Capital Expenditure
Cash Flow
+61.3%
$230K$371K

Capital expenditure jumped 61.3% — major investment cycle underway; assess returns on deployment.

Share Buybacks
Cash Flow
-58.2%
$20.0M$8.4M

Buyback activity reduced 58.2% — capital being redeployed elsewhere or cash conservation underway.

Total Liabilities
Balance Sheet
-35.9%
$5.1M$3.3M

Liabilities reduced 35.9% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-30.8%
$3.8M$2.6M

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
-17.8%
$813K$668K

R&D spending cut 17.8% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
-16.1%
$13.6M$11.4M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Accounts Receivable
Balance Sheet
-14%
$4.1M$3.5M

Receivables declined — improved collection efficiency or conservative revenue recognition.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-26
ADDED
As of June 30, 2025, the aggregate market value of the voting and nonvoting common equity held by non-affiliates of the registrant was $ 168,203,211 .
As of March 26, 2026, common shares outstanding are 3,185,025 .
The opportunity to apply solutions to recognized needs results from a core of practicing clinicians who introduce ideas to the Company, together with key employees who are both clinical applications savvy and development engineering adept.
Domestically, UTMD s medical devices are sold directly to clinical end-user facilities or designated stocking distributors for medical facilities.
UTMD has representation globally in the major developed countries as well as many underdeveloped countries through approximately 200 OUS distributors, 108 of which purchased at least five thousand dollars in UTMD medical devices during 2025.
+7 more — sign up free →
REMOVED
As of June 30, 2024, the aggregate market value of the voting and nonvoting common equity held by non-affiliates of the registrant was $ 216,013,098 .
As of March 25, 2025, common shares outstanding are 3,281,816 .
The opportunity to apply solutions to recognized needs results from an excellent core of practicing clinicians who introduce ideas to the Company, and key employees who are both clinical applications savvy and development engineering adept.
Domestically, UTMD s medical devices are sold directly to clinician end-user facilities or a designated stocking distributor for a medical facility.
UTMD has representation globally in the major developed countries as well as many underdeveloped countries through approximately 200 distributors, 104 of which purchased at least five thousand dollars in UTMD medical devices during 2024.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →